Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.

MLA

Gold, Ralf, et al. “Siponimod vs Placebo in Active Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis from the Phase 3 EXPAND Study.” Journal of Neurology, vol. 269, no. 9, Sept. 2022, pp. 5093–104. EBSCOhost, https://doi.org/10.1007/s00415-022-11166-z.

APA

Gold, R., Piani-Meier, D., Kappos, L., Bar-Or, A., Vermersch, P., Giovannoni, G., Fox, R. J., Arnold, D. L., Benedict, R. H. B., Penner, I.-K., Rouyrre, N., Kilaru, A., Karlsson, G., Ritter, S., Dahlke, F., Hach, T., & Cree, B. A. C. (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 269(9), 5093–5104. https://doi.org/10.1007/s00415-022-11166-z

Chicago

Gold, Ralf, Daniela Piani-Meier, Ludwig Kappos, Amit Bar-Or, Patrick Vermersch, Gavin Giovannoni, Robert J Fox, et al. 2022. “Siponimod vs Placebo in Active Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis from the Phase 3 EXPAND Study.” Journal of Neurology 269 (9): 5093–5104. doi:10.1007/s00415-022-11166-z.